دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Whom to Screen and How to Screen for Obstructive Sleep Apnea in the Cardiology Clinic.
Mansukhani, Meghna P. MD; Somers, Virend K. MD, PhD
doi : 10.1161/CIRCULATIONAHA.122.060899
Volume 147(8) pgs. 621-696,e92-e624 February 21, 2023
Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Wang, Xiaowen MD; Vaduganathan, Muthiah MD, MPH; Claggett, Brian L. PhD; Hegde, Sheila M. MD, MPH; Pabon, Maria MD; Kulac, Ian J. MS; Vardeny, Orly PharmD; O'Meara, Eileen MD; Zieroth, Shelley MD; Katova, Tzvetana MD; McGrath, Martina M. MBBCh; Pouleur, Anne-Catherine MD, PhD; Jhund, Pardeep S. MBChB, MSc, PhD; Desai, Akshay S. MD, MPH; Inzucchi, Silvio E. MD; Kosiborod, Mikhail N. MD; de Boer, Rudolf A. MD; Kober, Lars MD, DSci; Sabatine, Marc S. MD, MPH; Martinez, Felipe A. MD; Ponikowski, Piotr MD, PhD; Shah, Sanjiv J. MD; Hernandez, Adrian F. MD; Langkilde, Anna Maria MD, PhD; McMurray, John J.V. MD; Solomon, Scott D. MD; Lam, Carolyn S.P. MBBS, PhD
doi : 10.1161/CIRCULATIONAHA.122.062832
Sodium-glucose cotransporter-2 inhibitors have emerged as a key pharmacotherapy in heart failure (HF) with both reduced and preserved ejection fraction.
Consistency Breeds Confidence: The Continuing Story of SGLT2 Inhibitors.
Pina, Ileana L. MD, MPH
Stages of Valvular Heart Disease Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.
Shelbaya, Khaled MD, MSc; Claggett, Brian PhD; Dorbala, Pranav BS; Skali, Hicham MD, MSc; Solomon, Scott D. MD; Matsushita, Kunihiro MD; Konety, Suma MD; Mosley, Thomas H. PhD; Shah, Amil M. MD, MPH
doi : 10.1161/CIRCULATIONAHA.122.061396
Limited data exist on American College of Cardiology/American Heart Association valvular heart disease (VHD) stage prevalence, progression, and association with incident cardiovascular diseases in late life
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
Born, Emmanuelle PhD ,*; Lipskaia, Larissa PhD ,*; Breau, Marielle PhD ,*; Houssaini, Amal PhD; Beaulieu, Delphine PhD; Marcos, Elisabeth; Pierre, Remi PhD; Do Cruzeiro, Marcio PhD; Lefevre, Marine MD; Derumeaux, Genevieve MD, PhD; Bulavin, Dmitry V. PhD; Delcroix, Marion MD, PhD; Quarck, Rozenn PhD; Reen, Virinder MSc; Gil, Jesus PhD; Bernard, David PhD; Flaman, Jean-Michel PhD; Adnot, Serge MD, PhD; Abid, Shariq MD, PhD
doi : 10.1161/CIRCULATIONAHA.122.058794
Senescent cells (SCs) are involved in proliferative disorders, but their role in pulmonary hypertension remains undefined. We investigated SCs in patients with pulmonary arterial hypertension and the role of SCs in animal pulmonary hypertension models.
Are Senolytic Agents Guilty of Overkill or Inappropriate Age Discrimination?.
Rabinovitch, Marlene MD
Targeting Epsins to Inhibit Fibroblast Growth Factor Signaling While Potentiating Transforming Growth Factor-[beta] Signaling Constrains Endothelial-to-Mesenchymal Transition in Atherosclerosis.
Dong, Yunzhou PhD ,,*; Wang, Beibei MD, PhD ,,*; Du, Mulong MD, PhD ,*; Zhu, Bo MD, PhD; Cui, Kui PhD; Li, Kathryn PhD; Yuan, Ke PhD; Cowan, Douglas B. PhD; Bhattacharjee, Sudarshan PhD; Wong, Scott BS; Shi, Jinjun PhD; Wang, Da-Zhi PhD; Chen, Kaifu PhD; Bischoff, Joyce PhD; Linton, MacRae F. MD, PhD; Chen, Hong PhD
doi : 10.1161/CIRCULATIONAHA.122.063075
Epsin endocytic adaptor proteins are implicated in the progression of atherosclerosis; however, the underlying molecular mechanisms have not yet been fully defined. In this study, we determined how epsins enhance endothelial-to-mesenchymal transition (EndoMT) in atherosclerosis and assessed the efficacy of a therapeutic peptide in a preclinical model of this disease.
Pulling Out All the Stops: A Case of Progressive Dyspnea.
Ostrominski, John W. MD; Bhatt, Deepak L. MD, MPH; Scirica, Benjamin M. MD, MPH
Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study.
Felker, G. Michael MD, MHS; North, Rebecca PhD; Mulder, Hillary MS; Jones, W. Schuyler MD; Anstrom, Kevin J. PhD; Patel, Mahesh J. MD; Butler, Javed MD, MPH, MBA; Ezekowitz, Justin A. MD; Lam, Carolyn MBBS, PhD; O'Connor, Christopher M. MD; Roessig, Lothar MD; Hernandez, Adrian F. MD, MHS; Armstrong, Paul W. MD; for the VICTORIA Study Group
Letter by Liao Regarding Article, "Association Between Device-Measured Physical Activity and Incident Heart Failure: A Prospective Cohort Study of 94 739 UK Biobank Participants".
Liao, Bing MS
Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.
Tsao, Connie W. MD, MPH, FAHA, Chair; Aday, Aaron W. MD, MSc, FAHA; Almarzooq, Zaid I. MBBCh, MPH; Anderson, Cheryl A.M. PhD, MPH, FAHA; Arora, Pankaj MD, FAHA; Avery, Christy L. PhD, MPH, FAHA; Baker-Smith, Carissa M. MD, MPH, FAHA; Beaton, Andrea Z. MD, MS, FAHA; Boehme, Amelia K. PhD, MSPH; Buxton, Alfred E. MD; Commodore-Mensah, Yvonne PhD, MHS, RN, FAHA; Elkind, Mitchell S.V. MD, MS, FAHA; Evenson, Kelly R. PhD, MS, FAHA; Eze-Nliam, Chete MD, MPH; Fugar, Setri MD; Generoso, Giuliano MD, PhD; Heard, Debra G. PhD; Hiremath, Swapnil MD, MPH, FAHA; Ho, Jennifer E. MD, FAHA; Kalani, Rizwan MD; Kazi, Dhruv S. MD, MSc, MS, FAHA; Ko, Darae MD, MSc; Levine, Deborah A. MD, MPH; Liu, Junxiu PhD; Ma, Jun MD, PhD, FAHA; Magnani, Jared W. MD, MS, FAHA; Michos, Erin D. MD, MHS, FAHA; Mussolino, Michael E. PhD, FAHA; Navaneethan, Sankar D. MD, MS, MPH; Parikh, Nisha I. MD, MPH; Poudel, Remy MS, MPH, CPH; Rezk-Hanna, Mary PhD, FAHA; Roth, Gregory A. MD, MPH, FAHA; Shah, Nilay S. MD, MPH; St-Onge, Marie-Pierre PhD, FAHA; Thacker, Evan L. PhD; Virani, Salim S. MD, PhD, FAHA; Voeks, Jenifer H. PhD, FAHA; Wang, Nae-Yuh PhD, MS, FAHA; Wong, Nathan D. PhD, MPH, FAHA; Wong, Sally S. PhD, RD, CDN, FAHA; Yaffe, Kristine MD; Martin, Seth S. MD, MHS, FAHA, Vice Chair; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee
doi : 10.1161/CIR.0000000000001123
The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health.
Correction to: Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.
Correction to: Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation.
Correction to: Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women.
